CN100443086C - 人参皂苷-Re的制备方法 - Google Patents
人参皂苷-Re的制备方法 Download PDFInfo
- Publication number
- CN100443086C CN100443086C CNB2004100211136A CN200410021113A CN100443086C CN 100443086 C CN100443086 C CN 100443086C CN B2004100211136 A CNB2004100211136 A CN B2004100211136A CN 200410021113 A CN200410021113 A CN 200410021113A CN 100443086 C CN100443086 C CN 100443086C
- Authority
- CN
- China
- Prior art keywords
- water
- liquid
- ginsenoside
- raw material
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 37
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 37
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000011347 resin Substances 0.000 claims abstract description 27
- 229920005989 resin Polymers 0.000 claims abstract description 27
- 238000001953 recrystallisation Methods 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 18
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003480 eluent Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 44
- 235000002791 Panax Nutrition 0.000 claims description 43
- 241000208343 Panax Species 0.000 claims description 43
- 239000008399 tap water Substances 0.000 claims description 20
- 235000020679 tap water Nutrition 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 239000002893 slag Substances 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 238000011010 flushing procedure Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 12
- 229960003638 dopamine Drugs 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000019581 neuron apoptotic process Effects 0.000 abstract description 4
- 230000000274 adsorptive effect Effects 0.000 abstract description 3
- 210000001130 astrocyte Anatomy 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 abstract 5
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 abstract 5
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 2
- 206010034010 Parkinsonism Diseases 0.000 abstract 2
- 108010093625 Opioid Peptides Proteins 0.000 abstract 1
- 102000001490 Opioid Peptides Human genes 0.000 abstract 1
- 239000003399 opiate peptide Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 229930182494 ginsenoside Natural products 0.000 description 12
- 229940089161 ginsenoside Drugs 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000006837 decompression Effects 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100211136A CN100443086C (zh) | 2004-02-06 | 2004-02-06 | 人参皂苷-Re的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100211136A CN100443086C (zh) | 2004-02-06 | 2004-02-06 | 人参皂苷-Re的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1650876A CN1650876A (zh) | 2005-08-10 |
CN100443086C true CN100443086C (zh) | 2008-12-17 |
Family
ID=34868305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100211136A Expired - Fee Related CN100443086C (zh) | 2004-02-06 | 2004-02-06 | 人参皂苷-Re的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100443086C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1869056B (zh) * | 2006-06-21 | 2013-03-20 | 海南亚洲制药有限公司 | 一种从人参叶中提取分离人参皂苷混合物的方法 |
CN1869048B (zh) * | 2006-06-21 | 2012-10-03 | 海南亚洲制药有限公司 | 一种从人参叶中提取分离f组人参皂苷的方法 |
CN101597314B (zh) * | 2008-06-06 | 2012-01-04 | 北京本草天源药物研究院 | 一种人参皂苷Rg1的制备方法 |
US10300030B2 (en) | 2013-08-29 | 2019-05-28 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition |
CN104957714A (zh) * | 2015-05-26 | 2015-10-07 | 高健铭 | 预防老年期脑神经元损伤的复方西洋参精油饮品 |
CN108310031B (zh) * | 2018-04-28 | 2020-12-25 | 吉林吉春制药股份有限公司 | 一种人参果总皂苷原料药、制剂、制备方法、及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1242374A (zh) * | 1998-07-22 | 2000-01-26 | 北京市鑫利恒医药科技发展有限公司 | 人参皂甙Re的提取工艺及其新的药物用途 |
-
2004
- 2004-02-06 CN CNB2004100211136A patent/CN100443086C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1242374A (zh) * | 1998-07-22 | 2000-01-26 | 北京市鑫利恒医药科技发展有限公司 | 人参皂甙Re的提取工艺及其新的药物用途 |
Non-Patent Citations (2)
Title |
---|
人参皂苷Rg1对MPTP诱导的黑质神经元凋亡的保护作用及其机制. 陈晓春,陈滢.2001中国药学会学术年会大会报告集. 2001 |
人参皂苷Rg1对MPTP诱导的黑质神经元凋亡的保护作用及其机制. 陈晓春,陈滢.2001中国药学会学术年会大会报告集. 2001 * |
Also Published As
Publication number | Publication date |
---|---|
CN1650876A (zh) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101054377B (zh) | 夏天无总生物碱提取物、其制备方法、含该总生物碱提取物的药物组合物及其应用 | |
CN1935820A (zh) | 无患子总皂苷的制备方法 | |
CN102406833B (zh) | 一种麦冬的综合提取利用技术 | |
CN102283870A (zh) | 一种高纯度银杏叶组合物,含其制剂及其制备方法 | |
CN102178720A (zh) | 一种从绞股蓝中同时制备总皂苷和多糖的方法 | |
CN100443086C (zh) | 人参皂苷-Re的制备方法 | |
CN101695520A (zh) | 治疗糖尿病药物的制备方法 | |
CN105232584A (zh) | 珍贵植物中药材的免煎提取工艺 | |
CN100479833C (zh) | 一种远志精制总皂苷的提取方法 | |
CN102727548A (zh) | 一种人参茎叶总皂苷提取新技术及方法 | |
CN102343020B (zh) | 一种制备桂附地黄滴丸的工艺方法 | |
CN101830957A (zh) | 三七茎叶制备人参皂甙Rh2、Rg3的工艺方法 | |
CN102343021A (zh) | 一种制备桂附地黄胶囊的新工艺方法 | |
CN1994364B (zh) | 一种山豆根提取物的精制工艺 | |
CN1241923C (zh) | 夏天无总生物碱的提取方法及其新的用途 | |
CN113713076A (zh) | 一种增强免疫力防治病毒细菌的纯中药制剂及其制备方法 | |
CN101214325B (zh) | 复方陈香胃药物的制备方法及其新用途 | |
CN101371875A (zh) | 一种复方异常黑胆质成熟剂的总皂苷的提取制备方法 | |
CN106749487A (zh) | 一种从沙棘果皮中提取分离熊果酸的方法 | |
CN104744532A (zh) | 一种无患子皂苷的提取精制的方法 | |
CN1887309B (zh) | 一种防治骨质疏松及抑郁症的丹参有效部位群提取工艺 | |
CN101757091B (zh) | 治疗口腔溃疡的提取物组合制剂及其制备方法 | |
CN101584458A (zh) | 一种中老年清火化痰保健茶 | |
CN108904675A (zh) | 一种快速制备重楼提取物的方法 | |
CN103961551A (zh) | 一种治疗糖尿病的藏药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: CAO YINGLIN XU SUIXU SUN LIMEI LI WEILI Effective date: 20150617 Owner name: SHI DEWU Free format text: FORMER OWNER: XU Effective date: 20150617 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150617 Address after: 110000, No. 26, Lane 7, Yunshan mountain road, Huanggu District, Liaoning, Shenyang province 1-7-3 Patentee after: Shi Dewu Address before: 110016 School of traditional Chinese medicine, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Liaoning, Shenyang Patentee before: Xu Beibei Patentee before: Cao Yinglin Patentee before: Xu Suixu Patentee before: Sun Limei Patentee before: Li Weili |
|
ASS | Succession or assignment of patent right |
Owner name: LIAONING GUANGDA PHARMACEUTICAL INDUSTRY CO., LTD. Free format text: FORMER OWNER: SHI DEWU Effective date: 20150907 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150907 Address after: 118200, No. 45, the Yalu River Road, Kuandian Manchu Autonomous County, Liaoning City, Dandong province (Kuandian Town Industrial Zone South) Patentee after: Liaoning light too Pharmaceutical Co., Ltd. Address before: 110000, No. 26, Lane 7, Yunshan mountain road, Huanggu District, Liaoning, Shenyang province 1-7-3 Patentee before: Shi Dewu |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081217 Termination date: 20170206 |
|
CF01 | Termination of patent right due to non-payment of annual fee |